Oruka Therapeutics, Inc. ORKA Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance.
The official record: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Oruka Therapeutics, Inc.'s effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Oruka Therapeutics, Inc.'s effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount?
- Oruka Therapeutics, Inc. (ORKA) reported effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount of $5.83M in Q4 2025.
- How has Oruka Therapeutics, Inc.'s effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount changed year-over-year?
- Oruka Therapeutics, Inc.'s effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount decreased by 72.3% year-over-year, from $21.08M to $5.83M.
- What does effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount mean?
- This represents the impact of adjustments to the valuation allowance for deferred tax assets on the effective tax rate. It indicates management's assessment of the likelihood that the company will generate sufficient future taxable income to realize its deferred tax assets.